- Home
- GOSS vs TACH Comparison
GOSS vs TACH Comparison
Compare GOSS & TACH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOSS
- TACH
- Stock Information
- Founded
- GOSS 2015
- TACH 2024
- Country
- GOSS United States
- TACH United States
- Employees
- GOSS N/A
- TACH N/A
- Industry
- GOSS Biotechnology: Pharmaceutical Preparations
- TACH
- Sector
- GOSS Health Care
- TACH
- Exchange
- GOSS Nasdaq
- TACH Nasdaq
- Market Cap
- GOSS 347.8M
- TACH 350.2M
- IPO Year
- GOSS 2019
- TACH 2025
- Fundamental
- Price
- GOSS $2.47
- TACH $10.13
- Analyst Decision
- GOSS Strong Buy
- TACH
- Analyst Count
- GOSS 4
- TACH 0
- Target Price
- GOSS $8.50
- TACH N/A
- AVG Volume (30 Days)
- GOSS 3.1M
- TACH 357.0
- Earning Date
- GOSS 08-05-2025
- TACH 01-01-0001
- Dividend Yield
- GOSS N/A
- TACH N/A
- EPS Growth
- GOSS N/A
- TACH N/A
- EPS
- GOSS N/A
- TACH 0.19
- Revenue
- GOSS $40,237,000.00
- TACH N/A
- Revenue This Year
- GOSS N/A
- TACH N/A
- Revenue Next Year
- GOSS $30.65
- TACH N/A
- P/E Ratio
- GOSS N/A
- TACH $144.33
- Revenue Growth
- GOSS N/A
- TACH N/A
- 52 Week Low
- GOSS $0.66
- TACH $9.51
- 52 Week High
- GOSS $2.65
- TACH $11.00
- Technical
- Relative Strength Index (RSI)
- GOSS 68.08
- TACH N/A
- Support Level
- GOSS $2.38
- TACH N/A
- Resistance Level
- GOSS $2.65
- TACH N/A
- Average True Range (ATR)
- GOSS 0.15
- TACH 0.00
- MACD
- GOSS 0.03
- TACH 0.00
- Stochastic Oscillator
- GOSS 76.67
- TACH 0.00
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
About TACH Titan Acquisition Corp. Class A Ordinary Shares
Titan Acquisition Corp is a blank check company.